New England Peptide Introduces PepCRO™ - Industry's First Contract Research-based Service Taps NEP's Expertise in Peptide Design, Characterization and Process Feasibility


Gardner, MA
- New England Peptide (NEP) today announced that companies seeking expertise in peptide process feasibility, characterization or design can access NEP’s technical expertise through its PepCRO™ line of services.  PepCRO™, the first service of its kind in the market, allows customers to enter into short or long-term contracts where resources are committed to their peptide research and development project, allowing them access to all the expertise within NEP and extending their own research capabilities. 

"We are proud to offer this new cost-effective suite of R&D services in direct response to our customers’ requests,” said Dave Robinson, NEP’s CEO. “Our customers recognize that NEP’s role as an integrator of knowledge across the spectrum of peptide applications positions NEP’s team to help customers overcome the challenges in developing peptide-based drugs, vaccines and diagnostics.  PepCRO™ allows full access to our growing team of experts on a full-time equivalent basis.” 

PepCRO™ provides customers with a broad range of offerings from peptide design to characterization to research tool optimization. NEP’s day-to-day scientific leadership, including Dr. Robert Hammer and Dr. Ved Srivastava, coupled with support from its scientific advisory board comprised of the industry’s thought leaders, are spearheading delivery of this expertise to customers on projects such as scale-up (to 100s of grams), method development, novel modifications or otherwise complex projects. PepCRO™ customers will have a dedicated project manager, receive written reports and retain ownership of all intellectual property. Because of NEP’s broad expertise, the firm can work with PepCRO™ customers to create a flexible and cost effective program.  Further information on this service can be obtained from the Company’s website: .


About New England Peptide (
New England Peptide, announced founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company’s chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.

Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS. Peptides’ inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in research and clinical use.

# # #


"Thank you for the very quick response - if only all companies were as prompt as you!"
Mark B. PhD - John Innes Centre